Clinical Trials Logo
  1. Home
  2. Dyslipidemia
  3. NCT00326326
  4. Details
NCT00326326 Clinical Trial

Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes.

Dyslipidemia Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effect Of CP-778,875 On HDL-Cholesterol In Adult Subjects With Dyslipidemia And Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00326326
Other study ID # A5561005
Secondary ID
Status Completed
Phase Phase 2
First received May 12, 2006
Last updated May 6, 2009
Start date July 2006
Est. completion date June 2007

Study information
Verified date May 2009
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

To assess the effect of CP-778,875 on HDL-C cholesterol in adult subjects with dyslipidemia and type 2 diabetes

Recruitment information / eligibility
Status Completed
Enrollment 84
Est. completion date June 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria:

- HDL-C < or = 45 mg/dL for men and < or = 55 mg/dL for women

- Triglycerides between 150-500 mg/dL

- Fasting Plasma Glucose 140-240 mg/dL

Exclusion Criteria:

- Known cardiovascular, carotid, or peripheral vascular disease

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• CP-778,875

Locations
Country Name City State
United States Pfizer Investigational Site Anniston Alabama
United States Pfizer Investigational Site Atlanta Georgia
United States Pfizer Investigational Site Baltimore Maryland
United States Pfizer Investigational Site Bryan Texas
United States Pfizer Investigational Site Chicago Illinois
United States Pfizer Investigational Site Conyers Georgia
United States Pfizer Investigational Site DeFuniak Springs Florida
United States Pfizer Investigational Site Destin Florida
United States Pfizer Investigational Site Greenbrae California
United States Pfizer Investigational Site Houston Texas
United States Pfizer Investigational Site Huntsville Alabama
United States Pfizer Investigational Site Iowa City Iowa
United States Pfizer Investigational Site Jupiter Florida
United States Pfizer Investigational Site Kingsport Tennessee
United States Pfizer Investigational Site Las Vegas Nevada
United States Pfizer Investigational Site Lexington Kentucky
United States Pfizer Investigational Site Los Angeles California
United States Pfizer Investigational Site Melbourne Florida
United States Pfizer Investigational Site Milwaukee Wisconsin
United States Pfizer Investigational Site Mount Vernon New York
United States Pfizer Investigational Site Newport News Virginia
United States Pfizer Investigational Site Oklahoma City Oklahoma
United States Pfizer Investigational Site Omaha Nebraska
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site Richmond Virginia
United States Pfizer Investigational Site San Antonio Texas
United States Pfizer Investigational Site Springfield Missouri
United States Pfizer Investigational Site Tulsa Oklahoma
United States Pfizer Investigational Site Walnut Creek California
United States Pfizer Investigational Site Yakima Washington

Sponsors (1)
Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary HDL-C Safety and Efficacy
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT02837367 - Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People N/A
Active, not recruiting NCT02600338 - Meta-analyses of the Effect of Legumes on Blood Pressure N/A
Active, not recruiting NCT02223793 - Vascular Lifestyle-Intervention and Screening in Pharmacy N/A
Completed NCT02163044 - The Hellenic Postprandial Lipemia Study (HPLS)
Recruiting NCT01972113 - Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study) N/A
Recruiting NCT01705873 - Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen N/A
Completed NCT01764295 - Clinical Study for Patients With Hypertension Associated With Dyslipidemia Phase 3
Completed NCT01531062 - Effect of Nigella Sativa on Lipid Profiles in Elderly Phase 2
Terminated NCT01414166 - Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108) Phase 3
Completed NCT01990391 - Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities N/A
Recruiting NCT01670968 - HIV Reverse Cholesterol Transport Study
Completed NCT00977288 - A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029) Phase 2
Withdrawn NCT00664287 - Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) Phase 3
Completed NCT00768274 - Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol Phase 1/Phase 2
Completed NCT01285544 - The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia Phase 4
Completed NCT01483235 - Reduced Cardiac Rehabilitation Program N/A
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Completed NCT00309738 - Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Phase 3

External Links